Bank of America Corp DE Increases Stake in Amneal Pharmaceuticals, Inc. $AMRX

Bank of America Corp DE lifted its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 50.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 676,795 shares of the company's stock after buying an additional 225,637 shares during the period. Bank of America Corp DE owned approximately 0.21% of Amneal Pharmaceuticals worth $8,413,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Amneal Pharmaceuticals by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 94,638 shares of the company's stock valued at $793,000 after purchasing an additional 4,178 shares during the last quarter. Millennium Management LLC boosted its position in shares of Amneal Pharmaceuticals by 32.6% during the first quarter. Millennium Management LLC now owns 2,087,398 shares of the company's stock worth $17,492,000 after buying an additional 512,842 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in shares of Amneal Pharmaceuticals during the first quarter worth $244,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Amneal Pharmaceuticals by 5.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 334,956 shares of the company's stock valued at $2,807,000 after buying an additional 16,536 shares in the last quarter. Finally, Creative Planning grew its stake in shares of Amneal Pharmaceuticals by 61.9% in the second quarter. Creative Planning now owns 23,896 shares of the company's stock valued at $193,000 after buying an additional 9,136 shares in the last quarter. Institutional investors and hedge funds own 31.82% of the company's stock.

Amneal Pharmaceuticals Stock Performance

Shares of AMRX stock opened at $17.78 on Tuesday. The company has a current ratio of 2.20, a quick ratio of 1.44 and a debt-to-equity ratio of 77.65. The firm has a fifty day moving average price of $17.55 and a 200 day moving average price of $14.77. The company has a market cap of $5.68 billion, a P/E ratio of 36.29 and a beta of 1.27. Amneal Pharmaceuticals, Inc. has a 12 month low of $9.20 and a 12 month high of $19.26.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.30 earnings per share for the quarter, beating analysts' consensus estimates of $0.24 by $0.06. The company had revenue of $796.20 million for the quarter. Amneal Pharmaceuticals had a negative return on equity of 584.46% and a net margin of 5.05%.Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. Sell-side analysts predict that Amneal Pharmaceuticals, Inc. will post 0.94 earnings per share for the current fiscal year.

Insider Transactions at Amneal Pharmaceuticals

In other news, EVP Nikita Shah sold 146,403 shares of the business's stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $17.51, for a total transaction of $2,563,516.53. Following the completion of the sale, the executive vice president owned 253,390 shares in the company, valued at approximately $4,436,858.90. The trade was a 36.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director John Kiely sold 50,000 shares of the company's stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $17.64, for a total transaction of $882,000.00. Following the completion of the transaction, the director owned 210,252 shares of the company's stock, valued at approximately $3,708,845.28. The trade was a 19.21% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 413,016 shares of company stock valued at $7,216,567. Corporate insiders own 17.30% of the company's stock.

Analyst Upgrades and Downgrades

AMRX has been the subject of several research reports. Zacks Research raised Amneal Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Friday, August 7th. Wall Street Zen raised shares of Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Sunday, July 12th. Barclays raised their price objective on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an "overweight" rating in a research note on Wednesday, May 20th. UBS Group upped their target price on shares of Amneal Pharmaceuticals from $23.00 to $25.00 and gave the stock a "buy" rating in a research note on Monday, August 3rd. Finally, The Goldman Sachs Group reiterated a "buy" rating and set a $21.00 target price on shares of Amneal Pharmaceuticals in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, Amneal Pharmaceuticals presently has an average rating of "Buy" and an average price target of $17.67.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source